(Alliance News) - Indivior PLC on Tuesday said that its subsidiary, RBP Global Holdings Ltd, has completed the refinancing of a secured term loan. Read More
(Alliance News) - Indivior PLC on Thursday maintained its full year guidance and reported an improved third-quarter, as it looked to reassure the market after a profit warning a fortnight ago. Read More
(Alliance News) - Shares in Indivior PLC plunged on Thursday after the firm warned a competitor product was eating away at the firm's revenue. Read More
Indivior PLC - Richmond, Virginia-based specialty pharmaceuticals company - On Thursday, the company announced that Chair Graham Hetherington intends to retire from his role and the board at the end of the year for personal reasons. He has served as chair for four years and been a member of the board for five years. Indivior has started the search to identify a new chair. Read More
(Alliance News) - Indivior PLC on Wednesday said the primary and secondary endpoints were not met in a trial of AEF0117 in patients with cannabis use disorder. Read More
(Alliance News) - Stock prices in London opened lower on Thursday, with earnings from the UK and beyond largely falling short, after sentiment was already hurt by a tech sell-off in New York. Read More
(Alliance News) - London's FTSE 100 is called to open lower on Thursday, with a sell-off of US technology shares filtering through to trade in Europe and in Asia. Read More
(Alliance News) - Indivior PLC shares tumbled on Tuesday as it warned on profit amid weaker sales of a key opioid treatment, as well as a charge relating to a schizophrenia drug. Read More
(Alliance News) - Shares in Indivior PLC plunged on Tuesday after it flagged lower than expected sales of its opioid treatment, Sublocade, and said it expects to take a charge relating to schizophrenia drug, Perseris. Read More
(Alliance News) - Indivior PLC on Thursday confirmed that it has successfully transferred its primary listing to the Nasdaq Stock Market in the US. Read More
Indivior PLC - Chesterfield, Virginia-headquartered pharmaceutical maker - Reconfirms financial guidance for 2024 ahead of analyst 'teach-in' event in New York. Indivior also on Thursday is asking shareholders to approve moving its primary listing to New York from London. Read More
